Residual Cardiovascular Risk: What’s TMAO Got to do With it?

In the ongoing effort to further lower CV risk after LDL, HDL, LP(a), and A1C are treated, TMAO may soon be added as a target to the atherogenic alphabet soup.
Source: Consultant Live - Category: Primary Care Source Type: news